Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 7.00
SPHS's Cash to Debt is ranked higher than
68% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. SPHS: 7.00 )
SPHS' s 10-Year Cash to Debt Range
Min: 0.81   Max: No Debt
Current: 7

Equity to Asset 0.78
SPHS's Equity to Asset is ranked higher than
81% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SPHS: 0.78 )
SPHS' s 10-Year Equity to Asset Range
Min: 0.78   Max: 0.98
Current: 0.78

0.78
0.98
F-Score: 3
Z-Score: 0.72
M-Score: -2.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -195.80
SPHS's Operating margin (%) is ranked higher than
63% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. SPHS: -195.80 )
SPHS' s 10-Year Operating margin (%) Range
Min: -300   Max: -106.67
Current: -195.8

-300
-106.67
Net-margin (%) -222.98
SPHS's Net-margin (%) is ranked higher than
62% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. SPHS: -222.98 )
SPHS' s 10-Year Net-margin (%) Range
Min: -300   Max: -106.67
Current: -222.98

-300
-106.67
ROE (%) -27.68
SPHS's ROE (%) is ranked higher than
68% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. SPHS: -27.68 )
SPHS' s 10-Year ROE (%) Range
Min: -505.13   Max: -4.48
Current: -27.68

-505.13
-4.48
ROA (%) -21.49
SPHS's ROA (%) is ranked higher than
69% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. SPHS: -21.49 )
SPHS' s 10-Year ROA (%) Range
Min: -284.9   Max: -4.41
Current: -21.49

-284.9
-4.41
ROC (Joel Greenblatt) (%) -12551.28
SPHS's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. SPHS: -12551.28 )
SPHS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -23272.73   Max: -1153.21
Current: -12551.28

-23272.73
-1153.21
Revenue Growth (%) -25.30
SPHS's Revenue Growth (%) is ranked higher than
63% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. SPHS: -25.30 )
SPHS' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -25.3
Current: -25.3

EBITDA Growth (%) -18.10
SPHS's EBITDA Growth (%) is ranked higher than
67% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. SPHS: -18.10 )
SPHS' s 10-Year EBITDA Growth (%) Range
Min: -31   Max: 72.9
Current: -18.1

-31
72.9
EPS Growth (%) -16.30
SPHS's EPS Growth (%) is ranked higher than
71% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. SPHS: -16.30 )
SPHS' s 10-Year EPS Growth (%) Range
Min: -28.9   Max: 70.5
Current: -16.3

-28.9
70.5
» SPHS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

SPHS Guru Trades in

SPHS Guru Trades in

Q3 2013

SPHS Guru Trades in Q3 2013

Jean-Marie Eveillard 250,000 sh (New)
» More
Q4 2013

SPHS Guru Trades in Q4 2013

Jean-Marie Eveillard 250,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with SPHS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-09-30 New Buy$4.15 - $14.3 $ 3.27-62%250000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Sophiris Bio Inc

From The Land of What If - Smart Proteins and Debt Collectors
Today’s diverse companies were chosen for their speculative enterprises. Both companies deal in the territory of what if. If Encore Capital Group Inc. (ECPG) can collect more from a huge portfolio of consumer debt, the company would grow. If Sophiris Bio Inc. (SPHS), a 10-person biopharm, is successful in competing to provide relief for prostate BPH symptoms, the company would soar. Read more...
Sleepy Sector Wakes Up - Billionaires Hold Biotechs in 52-week Low
The biotech industry refers to 2013 as the year of the biotech return. Fourteen biotech companies had gone public as of May 2013, according to Reuters. By early August BioTechNow reported, “With 23 US-based biotech companies in 2013, the sector is now ahead of any year since 2007. The European-based biotechs (including companies based in Israel) continue to knock out a few IPOs per year, with four in 2013 so far.” Read more...

Ratios

vs
industry
vs
history
P/B 1.30
SPHS's P/B is ranked higher than
95% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. SPHS: 1.30 )
SPHS' s 10-Year P/B Range
Min: 1.3   Max: 6.29
Current: 1.3

1.3
6.29
P/S 5.25
SPHS's P/S is ranked higher than
72% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. SPHS: 5.25 )
SPHS' s 10-Year P/S Range
Min: 0   Max: 11.53
Current: 5.25

0
11.53
EV-to-EBIT 11.90
SPHS's EV-to-EBIT is ranked higher than
76% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. SPHS: 11.90 )
SPHS' s 10-Year EV-to-EBIT Range
Min: 21.5   Max: 41
Current: 11.9

21.5
41

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.40
SPHS's Price/Net Cash is ranked higher than
97% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. SPHS: 1.40 )
SPHS' s 10-Year Price/Net Cash Range
Min: 1.64   Max: 6.78
Current: 1.4

1.64
6.78
Price/Net Current Asset Value 1.40
SPHS's Price/Net Current Asset Value is ranked higher than
98% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. SPHS: 1.40 )
SPHS' s 10-Year Price/Net Current Asset Value Range
Min: 1.64   Max: 6.63
Current: 1.4

1.64
6.63
Price/Tangible Book 1.30
SPHS's Price/Tangible Book is ranked higher than
95% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. SPHS: 1.30 )
SPHS' s 10-Year Price/Tangible Book Range
Min: 1.49   Max: 6.56
Current: 1.3

1.49
6.56
Price/Median PS Value 0.70
SPHS's Price/Median PS Value is ranked higher than
84% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. SPHS: 0.70 )
SPHS' s 10-Year Price/Median PS Value Range
Min: 6.17   Max: 6.17
Current: 0.7

Earnings Yield (Greenblatt) 8.40
SPHS's Earnings Yield (Greenblatt) is ranked higher than
77% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. SPHS: 8.40 )
SPHS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.4   Max: 8.6
Current: 8.4

2.4
8.6
Forward Rate of Return (Yacktman) -114.62
SPHS's Forward Rate of Return (Yacktman) is ranked higher than
54% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. SPHS: -114.62 )
SPHS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -34.4   Max: -19.9
Current: -114.62

-34.4
-19.9

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:SHS.Canada, BFF1.Germany
Sophiris Bio Inc was formed in May 2003 under the predecessor to the Business Corporations Act by the amalgamation of Stratos Biotechnologies Inc., Nucleus BioScience Inc. and Brightwave Ventures Inc. It began operations on January 11, 2002. The Company's operations were initially located in Vancouver, British Columbia. Effective April 2, 2012, the Company changed its name from Protox Therapeutics Inc. to Sophiris Bio Inc. The Company is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of urological diseases. It is currently developing PRX302 for treatment of the symptoms of benign prostatic hyperplasia. BPH is a non-cancerous enlargement of the prostate gland that commonly affects men who are age 50 and older. The Company expects that PRX302 will compete with the current treatment options for the symptoms of BPH, which include oral drug therapy and surgery. Its business and operations are subject to a variety of U.S. federal, state and local, and foreign supranational, national, provincial and municipal laws, regulations and trade practices. As of December 31, 2012, it had nine full-time employees and one part-time employee.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide